AMETEK, Inc.

Executive Summary

SELL, Medium conviction. Rated SELL, Medium conviction. AME has real operating momentum, including 10% Q2 organic sales growth, a record $4.11B backlog, and raised FY26 EPS guidance, but the shares trade at 35.99x TTM earnings versus a 27.5x peer average and only 5.3% below their 52-week high. The issue is not business quality. It is paying a premium valuation before the large Indicor acquisition closes and before Q3 growth moderation is resolved.

Investment Thesis

AME's current share price assumes that a very good business will remain in a very favorable part of its cycle. That can happen. The record $4.11B backlog and June order strength show that demand is not yet rolling over, and management has earned the benefit of the doubt on ordinary operations. The company converted Q2 demand into a $2.09 adjusted EPS result, above its own guide, while core operating margin reached 27.1%. Those are characteristics of a high-quality industrial compounder.

The problem is the entry price. At $247.36, investors are underwriting roughly 30x the midpoint of FY26 adjusted EPS guidance before taking on the integration of a $5B acquisition. That valuation leaves little tolerance for the ordinary slowing that management already signals in Q3, or for the Process portfolio's mid-single-digit growth outlook. A premium can be justified for AME's cash conversion and specialized franchises. It is harder to justify when the target price mix points to $141.09 under P/S, $157.10 under DCF, and only the quality-adjusted method supports a value above the market.

The case depends on three outcomes. First, the order book must turn into sustained organic growth after Q3 rather than normalize toward mid-single digits. Second, FARO must show the promised margin improvement over the next 6-12 months. Third, Indicor must close in 2H26 and deliver the stated 10%-12% cost synergies without impairing AME's historically disciplined balance sheet. Each is plausible, but the market already appears to give substantial credit for all three.

Conviction remains Medium rather than High because AME is not a fragile cyclical story. Cash flow is strong, debt is low before the acquisition, and management's eight consecutive reported EPS beats demonstrate operational control. Still, a high-quality company is not automatically a good stock at any price. The preferred stance is to reduce exposure into the November earnings event and revisit after either a material price reset or proof that the post-Indicor earnings base can support the premium valuation.

Key Metrics

Financial Strength

AME's financial profile is sound before the pending Indicor transaction. Low leverage, strong free-cash generation, and a 1.21 current ratio as of June 30, 2026 give management meaningful financing flexibility. Profitability has held near the mid-20s at the operating line despite tariff and inflation pressure, and management said pricing exceeded those costs in Q2. The main balance-sheet question is not liquidity today. It is whether a much larger acquisition preserves the company's historically high returns and cash conversion after closing.

Competitive Position

AME earns returns through niche instruments and engineered components embedded in customers' regulated workflows, where accuracy, certification, installed-base service, and qualification cycles make substitution costly. Its acquisition model broadens those protected niches, including FARO's 3D measurement and Indicor's specialty instrumentation. The moat remains durable in core applications, but it is not immune to AI-enabled design tools, lower-cost sensor competition, or shortened technology cycles in semiconductor and automation markets.

Management & Guidance

Management raised FY26 expectations after Q2, calling for about 10% overall sales growth, mid- to high-single-digit organic growth, and $8.20-$8.30 of adjusted diluted EPS. Q3 guidance calls for high-single-digit overall sales growth and $2.08-$2.10 of adjusted EPS, so management is signaling moderation rather than extrapolating the quarter's 25% order growth. Guidance deserves more credibility than usual given the eight-quarter beat streak and Q2's outperformance versus management's own range, though the $6M of acquisition diligence expense and the pending Indicor close create a new source of estimate risk.

Segment Analysis

• Electronic Instruments Group, EIG (Not disclosed in supplied data): Q2 organic sales grew 7%; test and measurement, process analytics, and semiconductor-oriented metrology remain key demand vectors.
• Electromechanical Group, EMG (Not disclosed in supplied data): Q2 organic sales grew 15%, leading both major operating groups on aerospace, automation, and engineered-component demand.
• Process business (Not disclosed in supplied data): Management guides FY26 sales growth at only mid-single digits, making it the relative weak point in the current portfolio outlook.
• Geographic revenue (Not disclosed in supplied data): Growth capacity investment spans the U.S., Serbia, Mexico, and Poland, but no geographic revenue split was provided.

Capital Allocation

The balance sheet enters the Indicor transaction from a position of strength, with $1.8B LTM free cash flow through June 30, 2026 and 0.95x LTM debt/EBITDA. Management plans $160M of FY26 capital expenditure, with roughly two-thirds directed to growth capacity, while the deep-dive cash-flow feed records $0.5B of free cash flow, $0.1B of dividends, and no reported buybacks for its measured period. The priority is clearly acquisitions and organic capacity rather than financial engineering, which is sensible only if the $5B Indicor deal earns above its cost of capital.

Management Execution & Track Record

Management has established strong quarterly credibility: AME beat Street EPS expectations in each of the last eight reported quarters, by 1.1% to 7.4%, including Q2 FY26 EPS of $2.09 versus a $1.99 consensus estimate. In the 2024 Q3 call, management raised FY24 adjusted EPS guidance to $6.77-$6.82, expected 5%-7% sales growth, and targeted 115%-120% free-cash-flow conversion while navigating a 2% organic-sales decline and continuing destocking. Supplied data do not include FY24 actual results, so full-year delivery against that guide cannot be verified directly; however, FY25 operating margin rose to 26.2% from 25.6%, and current management has again raised expectations to FY26 EPS of $8.20-$8.30 with 110%-115% conversion. The strategic direction has shifted from absorbing destocking and smaller technology tuck-ins such as Virtek Vision to deploying capital into the much larger Indicor acquisition. Operators look credible, but acquisition scale now raises the proof threshold.

Positioning & Flows

Institutional ownership is concentrated, with the top three institutions holding 78.3% and insider ownership only 0.3%, leaving the shareholder base dependent on professional investors maintaining a premium-quality allocation. Short interest is modest at 1.66%, or 3.80M shares, with 2.9 days to cover, so there is little evidence of a crowded bearish trade or meaningful short-squeeze fuel. Options gamma is reported positive for expiries within 45 days, which can dampen near-term volatility, but the supplied data do not quantify zero-gamma or call and put walls.

Bull Case

• Q2 adjusted EPS of $2.09 exceeded management's $1.96-$2.00 guide, while organic revenue grew 10%.
• Core operating margin expanded 110 bps year over year to 27.1% in Q2, showing pricing more than covered inflation and tariffs.
• EMG grew organic sales 15% in Q2 and EIG grew 7%, giving the current upcycle breadth across both operating platforms.
• FY26 free-cash-flow conversion is guided to 110%-115% of net income after Q2 free cash flow rose 37% to $452M.

Bear Case

• The 35.99x TTM P/E is 31% above the 27.5x average across 10 peers, despite a wide 3.0x peer valuation dispersion that weakens simple relative-value support.
• Q3 organic sales growth is guided only to high single digits, below Q2's 10% organic growth, while the Process business is expected to grow only mid-single digits for FY26.
• Indicor's $5B purchase is material relative to AME's $56.7B market capitalization, and the investment case requires management to deliver the stated 10%-12% synergy target.
• The quality framework assigns only 5/100 to innovation investment and 38/100 to valuation appeal, a weak combination if industrial technology demand normalizes.

Valuation & Price Target

Engine price target $200.97 (-18.8% vs current), Medium confidence.

• P/E Multiple: $211.6 (28% weight)
• P/S Multiple: $141.09 (20% weight)
• Quality-adjusted: $263.19 (20% weight)
• DCF: $157.1 (8% weight)

The rating agrees with the quantitative SELL baseline and its $200.97 target because valuation, rather than operating performance, dominates the 6-12 month setup. The engine's four methods span $141.09 on P/S to $263.19 on quality-adjusted value, and the 3.0x peer dispersion makes the peer-multiple component inherently noisy. AME's raised FY26 EPS guide, 0.95x LTM debt/EBITDA, and eight-quarter beat record prevent a High-conviction Sell, but they do not erase a 35.99x TTM P/E against 27.5x peers. Sell-side consensus is Strong Buy from 7 buys and 3 holds, but it is explicitly low-signal context and does not resolve the valuation gap.

Risk Assessment

Risk score 45/100 (Moderate). The largest downside risk is that FY26's $8.20-$8.30 EPS guide becomes the earnings ceiling rather than the floor, exposing a roughly 30x forward P/E to a sharp de-rating.

The Bottom Line

AME rates a SELL at Medium conviction for the next 6-12 months. The business is executing well, and the November 3 report could remain supported by low short interest and positive options gamma. But the stock already reflects much of that strength at a valuation materially above peers and near its five-year high. A more positive view would require either a price near the $200.97 base-case value or clear evidence that Indicor synergies and backlog conversion can lift earnings beyond the present FY26 guide.